| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.04 | 0.4 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | -0.11 | 0.4 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | selumetinib:vorinostat (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |